SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a…
SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid
- Product
- galinpepimut-S (GPS)
- Milestone
- topline data
- Indication
- acute myeloid leukemia (AML)
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The disclosure provides newly reported, statistically significant overall survival improvement versus investigator’s choice of best available treatment, plus a stated plan to meet the FDA and prepare for a BLA submission in 1H 2027 using an accelerated filing strategy.
Market read
Traders can reassess near-term biotech risk as the company moves from late-stage clinical uncertainty toward a defined regulatory pathway with accelerated BLA preparations.
What to watch
FDA feedback on accelerated filing strategy and the eventual BLA review timeline remain key uncertainties, and the trial’s open-label design could affect interpretation despite the OS endpoint.
Background
The 8-K (Item 7.01 Regulation FD, Item 8.01 Other Events) announces topline results from the pivotal randomized Phase 3 REGAL trial of galinpepimut-S (GPS) as AML maintenance monotherapy in patients ineligible for or unable to undergo allogeneic stem cell transplantation.
Ticker impact
SELLAS reports positive pivotal Phase 3 REGAL OS results for galinpepimut-S, including HR 0.59 (p=0.035) and plans for FDA BLA discussions.
Likely upward bias as investors price in improved FDA odds and a clearer path to an accelerated BLA filing timeline.
The filing plan (accelerated strategy, BLA prep in 1H 2027) is directly tied to the newly disclosed primary endpoint results, which are typically material for biotech valuation and near-term sentiment.
Market effects
Adds incremental validation for WT1-targeted immunotherapeutic vaccine approaches in AML maintenance, potentially supporting sentiment for similar immunotherapy platforms.
Primarily US biotech sentiment; could influence pre-market positioning in small-cap oncology vaccine peers.
Limited direct global read-through, but reinforces the broader appetite for late-stage oncology immunotherapy data.
Counterpoint
OS benefit is based on topline primary endpoint analysis after 80 deaths; investors may wait for full secondary endpoint and subgroup details before fully de-risking regulatory outcomes.
Key entities
- companySELLAS Life Sciences Group, Inc.
Subject of the 8-K; reports positive pivotal Phase 3 REGAL OS results for GPS and outlines FDA engagement and BLA preparation plans.
- productGalinpepimut-S (GPS)
WT1-targeted immunotherapeutic cancer vaccine evaluated as AML maintenance monotherapy in REGAL.
- clinical_trialREGAL trial
Phase 3 randomized registrational trial evaluating GPS in AML patients in second or later remission who cannot undergo allogeneic stem cell transplantation.
- regulatorU.S. Food and Drug Administration (FDA)
Company plans to meet to discuss accelerated filing strategy and regulatory path forward.

